Table 2.
Licensed IFN-I in the United States.
| Proprietary Name | Proper Name | Dosage Form | Dosage | Route | Indication | Expression System |
|---|---|---|---|---|---|---|
| Avonex | IFNβ-1a | 30 µg/0.5 ml | 30 µg per week | IM | Multiple sclerosis including relapsing-remitting and secondary active disease | CHO cells |
| Rebif | IFNβ-1a | 8.8 µg/0.2 ml 22/44 µg/0.5 ml |
22 or 44 µg 3 times per week | SC | CHO cells | |
| Plegridy | IFNβ-1a | 63/94/125 µg/0.5 ml | 125 µg every 14 days | SC | CHO Cells | |
| Betaseron | IFNβ-1b | 0.3 mg | 0.25 mg every other day | SC | E. coli | |
| Extavia | IFNβ-1b | 0.3 mg | 0.25 mg every other day | SC | E. coli | |
| Pegasys | Peg IFNα2a | 180 µg | Adult: 180 ug per week Pediatric: 180 ug/1.73 m2 | SC | Chronic Hepatitis C, Chronic Hepatitis B | E. coli |
| Pegintron | Peg IFNα2b | 50/80/120/150 µg/0.5 ml | Adult: 1.5 ug/Kg/week Pediatric: 60 ug/m2/week | SC | Chronic Hepatitis C in patients with compensated liver disease | E. coli |
| Intron A | IFNα2b | 10/18/25 MIU | Diagnosis Dependent | IV, IM, SC, IL | Hairy Cell Leukemia, Malignant Melanoma, Follicular Lymphoma, Condylomata Acuminata, AIDS-related Kaposi’s Sarcoma, Chronic Hepatitis C, Chronic Hepatitis B | E. coli |
| Sylatron | Peg IFNα2b | 200/300/600 µg | 6 ug/Kg/week for 8 weeks then 3 ug/Kg/week for up to 5 years | SC | Melanoma with metastasis to lymph nodes–to begin within 84 days of surgical resection | E. coli |
Peg, polyethylene glycol; MIU, million international units; BSA; IM, intramuscular; IV, intravenous; IL, intralesional; SC, subcutaneous; CHO, Chinese hamster ovary cells.